Navigation Links
SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs
Date:3/29/2011

months ended December 31, 2010, compared to $4.9 million for the same period in 2009, primarily due to a reduction in personnel related costs through reductions in employees and in executive compensation.

Research and development expenses decreased 53%, or $1.2 million, to $1.2 million for the twelve months ended December 31, 2010, compared to $2.4 million for the same period in 2009, primarily due to reductions in personnel and other expenses reflecting the deferral of development activities for certain product candidates.

The net loss for the twelve months ended December 31, 2010, decreased 54%, or $3.7 million, to $3.2 million, compared with a net loss of $6.9 million for the same period in 2009. This decrease was primarily due to lower overall operating expenses.  

As of December 31, 2010, the Company had approximately $1.9 million in cash and cash equivalents, and $257,000 in restricted cash.  Based on its current operating plan, the Company anticipates that existing cash and cash equivalents, will be sufficient to fund its operations into the second quarter of 2011, provided that it may experience additional constraints on its liquidity based on the timing of inventory requirements necessary to fulfill anticipated orders of its nutritional products, or as a result of other unforeseen events.  The Company is actively managing its liquidity by limiting clinical and development expenses to its lead products and supporting existing alliances and collaborations.

The Company has implemented expense reduction strategies to reduce operating costs and preserve cash. The Company's board of directors has agreed to defer their quarterly cash retainer and the Company has deferred all significant expenditures on new projects pending additional financing or partnership support.

The Company also announced today that it has restated its financial statements for the quarters ended March 31, 2010, June 30, 2010, and Septembe
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. SCOLR Pharma, Inc. Receives Deficiency Letter from FDA on Pseudoephedrine Application
2. SCOLR Pharma, Inc. Retains Nicholas Hall & Company
3. SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
4. SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange
5. SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
6. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
7. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
8. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
9. SCOLR Pharma, Inc. Licenses Dietary Supplements
10. SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards
11. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today ... diagnostic platform during a special event at the company,s ... , on September 5, 2014. The event, which will ... the ApolloDx website, www.apollodx.com .    ... testing," said Jared Bauer , Co-Founder and Managing ...
(Date:8/20/2014)... 20, 2014 Trovagene, Inc. (NASDAQ:   TROV), ... results from two clinical studies will be presented at ... urine-based diagnostic test for the detection of high risk ... scheduled to take place in Seattle ... . Additionally, a new U.S. patent was issued earlier ...
(Date:8/20/2014)... England , August 20, 2014 ... be Conducted in the US  KalVista Pharmaceuticals ... macular edema (DME), today announces that it has begun ... novel plasma kallikrein inhibitor, KVD001, for the treatment of ... Sun of the Beetham Eye Institute, Joslin Diabetes Center; ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Sept. 18 A long-term study found,that a ... with life-threatening,diseases, such as leukemia and lymphoma, results ... males are likely to recover,from these changes over ... In addition, neither male nor female long-term cancer,survivors ...
... Bacterial Infection and May ... Bacterial Infections, BOSTON, Sept. 18 Paratek ... of the Company,s,Multiple Adaptation Response (MAR) inhibitor program. ... controlling virulence and antibiotic,resistance. Paratek has shown that ...
Cached Medicine Technology:Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 2Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 3Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 4Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 2Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 3Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 4
(Date:8/20/2014)... of brain cells that act as a "sleep switch" ... and staying asleep, a new study suggests. In ... often results in nighttime confusion and wandering, according to ... Rush Memory and Aging Project, which includes nearly 1,000 ... followed until death, at which point their brains are ...
(Date:8/20/2014)... By Kathleen Doheny ... -- Breast reconstruction after a mastectomy has long been an ... percent of women choose it. "The most common reasons ... important, they weren,t interested in more surgery or they were ... Morrow, chief of breast surgery at Memorial Sloan Kettering Cancer ...
(Date:8/20/2014)... persistent and deadliest infectious diseases in the world, killing ... who study tuberculosis have long debated its origins. New ... Africa to seals and sea lions that brought the ... people there before Europeans landed on the continent. , ... Source of New World Human Tuberculosis," was published in ...
(Date:8/20/2014)... With 3943.8% growth, Connexion Point ranks number ... fastest growing companies. The Inc. 500 ranks Connexion Point 12th, ... Point is the #1 fastest growing company in Utah. , ... and its clients include four of the top 10 health ... and has offices and contact centers in Salt Lake City, ...
(Date:8/20/2014)... YORK, NY (August 20, 2014) Research from Columbia ... critical role in stomach cancer growth and that blocking ... an effective treatment for the disease. The study was ... in collaboration with Duan Chen, MD, PhD, in Norway ... Translational Medicine . , "Scientists have long observed that ...
Breaking Medicine News(10 mins):Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... the pioneer and largest provider of retail-based health care in the ... test at its 23 locations inside select CVS/pharmacy stores in the ... in partnership with Rapid Pathogen Screening, Inc (RPS). MinuteClinic hopes ... clinic locations in 25 states. , , The ...
... , ENCINITAS, Calif., Aug. 11 DRJ Group ... today announced a new awareness and fundraising initiative with the Arthritis ... portion of each Stopain purchase to support the Foundation,s mission to ... is issuing a just-released video - Stop Pain. Start Dancing ...
... , , NEW YORK, Aug. 11 ... bank has acquired Park Avenue Fertility, located in the heart of ... bank will be able to offer local services in both Los ... reproductive medicine. , , "California Cryobank has ...
... , , NEW YORK, Aug. ... a contract by ValueOptions(R), a behavioral health care company headquartered ... services for ValueOptions(R) at risk Plans, which cover approximately 1.5 ... Medicaid members that have other healthcare coverage, and recover overpayments ...
... , , , ... that many claim to value personal responsibility, yet the lack of ... less responsible than they take credit for being. , , ... While the decisions made by those running large corporations influenced the ...
... , TROY, Mich., Aug. 11 CareTech Solutions, Inc. ... inform a tion t echnology (IT) and ... provider for hospitals and health systems nationwide, announced today it has signed a three-year ... e gri s -health.com ), based in Oklahoma. , ...
Cached Medicine News:Health News:MinuteClinic Offers New Rapid Pink-Eye Test; Detects Viral Conjunctivitis Infections in Minutes 2Health News:MinuteClinic Offers New Rapid Pink-Eye Test; Detects Viral Conjunctivitis Infections in Minutes 3Health News:Photo: Stopain and the Arthritis Foundation Join Forces to Promote the Benefits of Staying Active 2Health News:Nation's Leading Sperm Bank Opens Branch in New York City 2Health News:ValueOptions(R) Awards Coordination of Benefits and Overpayment Services Contract to HMS 2Health News:Author Alison Stein Identifies Widespread Crisis in Personal Responsibility, Outlines Path to Solution in Reality 2Health News:CareTech Signs Three-Year Agreement to Provide Web Services to INTEGRIS Health's 13 Hospitals 2Health News:CareTech Signs Three-Year Agreement to Provide Web Services to INTEGRIS Health's 13 Hospitals 3
... Lipoprint System is a high resolution diagnostic test ... by other methods. The test procedure is simple ... hours. Any abnormal value is clearly flagged. A ... atherogenic, small dense LDL in red and the ...
... is the only control for ... patient synovial fluid samples performed ... is also an aid for ... indicate a pathological condition present ...
... Suitable for use with Leica ... bilirubinometers (pediatric) and all automated ... including Aeroset, AU Series, Cobas, ... These controls contain purified bilirubin ...
... designed for point-of-care dipstick control. Its unique, ... problems and provides maximum portability ideal ... is the addition of creatinine and microalbumin. ... results for hCG for early pregnancy detection ...
Medicine Products: